Literature DB >> 35554914

Measuring Neutralizing Antibodies to SARS-CoV-2 Using Lentiviral Spike-Pseudoviruses.

Sabari Nath Neerukonda1, Russell Vassell1, Carol D Weiss2, Wei Wang3.   

Abstract

Assays measuring neutralizing antibodies (nAbs) against SARS-CoV-2 are used to evaluate serological responses after SARS-CoV-2 infection and the potency of therapeutic antibodies and preventive vaccines. It is therefore imperative that neutralization assays be sensitive, specific, quantitative, and scalable for high throughput. Pseudoviruses are excellent surrogates for highly pathogenic viruses such as SARS-CoV-2 because they can be safely used to measure nAbs in a biosafety level-2 laboratory. In addition, pseudoviruses allow for easy introduction of mutations to study the effect of amino acid changes in the spike protein. In this chapter, we describe a recently optimized assay for measuring neutralizing antibodies to SARS-CoV-2 that uses a HIV-based lentiviral vector pseudotyped with the spike glycoprotein of SARS-CoV-2 to infect 293T cells stably expressing ACE2 and TMPRSS2.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Assay optimization; Luciferase reporter; Neutralizing antibodies; Pseudovirus; SARS-CoV-2

Mesh：

Substances：

Year:  2022        PMID： 35554914     DOI： 10.1007/978-1-0716-2111-0_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  5 in total

1.  A serological assay to detect SARS-CoV-2 seroconversion in humans.

Authors:  Fatima Amanat; Daniel Stadlbauer; Shirin Strohmeier; Thi H O Nguyen; Veronika Chromikova; Meagan McMahon; Kaijun Jiang; Guha Asthagiri Arunkumar; Denise Jurczyszak; Jose Polanco; Maria Bermudez-Gonzalez; Giulio Kleiner; Teresa Aydillo; Lisa Miorin; Daniel S Fierer; Luz Amarilis Lugo; Erna Milunka Kojic; Jonathan Stoever; Sean T H Liu; Charlotte Cunningham-Rundles; Philip L Felgner; Thomas Moran; Adolfo García-Sastre; Daniel Caplivski; Allen C Cheng; Katherine Kedzierska; Olli Vapalahti; Jussi M Hepojoki; Viviana Simon; Florian Krammer
Journal:  Nat Med       Date:  2020-05-12       Impact factor: 53.440

2.  Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery.

Authors:  R Zufferey; T Dull; R J Mandel; A Bukovsky; D Quiroz; L Naldini; D Trono
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

3.  The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade.

Authors:  B Coutard; C Valle; X de Lamballerie; B Canard; N G Seidah; E Decroly
Journal:  Antiviral Res       Date:  2020-02-10       Impact factor: 5.970

4.  Generation of MERS-CoV Pseudotyped Viral Particles for the Evaluation of Neutralizing Antibodies in Mammalian Sera.

Authors:  Abdulrahman Almasaud; Naif Khalaf Alharbi; Anwar M Hashem
Journal:  Methods Mol Biol       Date:  2020

5.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582
  5 in total
  1 in total

1.  Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.

Authors:  Sabari Nath Neerukonda; Richard Wang; Russell Vassell; Haseebullah Baha; Sabrina Lusvarghi; Shufeng Liu; Tony Wang; Carol D Weiss; Wei Wang
Journal:  J Virol       Date:  2022-08-24       Impact factor: 6.549
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.